Cargando…
SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea
OBJECTIVE: This pivotal phase III study, SIAXI, investigated the efficacy and safety of incobotulinumtoxinA for the treatment of chronic sialorrhea due to Parkinson disease (PD), atypical parkinsonism, stroke, or traumatic brain injury (TBI). METHODS: Adult patients with PD (70.7%), atypical parkins...
Autores principales: | Jost, Wolfgang H., Friedman, Andrzej, Michel, Olaf, Oehlwein, Christian, Slawek, Jaroslaw, Bogucki, Andrzej, Ochudlo, Stanislaw, Banach, Marta, Pagan, Fernando, Flatau-Baqué, Birgit, Csikós, János, Cairney, Claire J., Blitzer, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511076/ https://www.ncbi.nlm.nih.gov/pubmed/30918101 http://dx.doi.org/10.1212/WNL.0000000000007368 |
Ejemplares similares
-
Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI
por: Berweck, Steffen, et al.
Publicado: (2021) -
Safety Profile and Lack of Immunogenicity of IncobotulinumtoxinA in Pediatric Spasticity and Sialorrhea: A Pooled Analysis
por: Berweck, Steffen, et al.
Publicado: (2022) -
Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions
por: Makino, Koji, et al.
Publicado: (2020) -
Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA
por: Fheodoroff, Klemens, et al.
Publicado: (2020) -
Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study
por: Wissel, Jörg, et al.
Publicado: (2017)